摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

S-(1-naphthylmethyl)thioacetimidate hydrochloride | 210354-37-3

中文名称
——
中文别名
——
英文名称
S-(1-naphthylmethyl)thioacetimidate hydrochloride
英文别名
Naphthalen-1-ylmethyl ethanimidothioate;hydrochloride
S-(1-naphthylmethyl)thioacetimidate hydrochloride化学式
CAS
210354-37-3
化学式
C13H13NS*ClH
mdl
——
分子量
251.78
InChiKey
WZOXMZCQBCMNOR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.75
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    50.9
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Nitric oxide synthase inhibitors
    申请人:——
    公开号:US20020010366A1
    公开(公告)日:2002-01-24
    The present invention relates to novel amidino compound of formula (I). 1 to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.
    本发明涉及一种新的式(I)的酰胺化合物,其制备方法,含有它们的药物组合物,以及它们在治疗中的应用,特别是作为诱导型一氧化氮合酶的选择性抑制剂的用途。
  • Nitric oxide synthase inhibitor phosphate salt
    申请人:——
    公开号:US20040087654A1
    公开(公告)日:2004-05-06
    A compound of formula (I): namely (2S)-2-amino-4-{[2-(etha-nimidoylamino)ethyl]thio}butanoic acid, compound with prosphoric acid, or a solvate or physiologically functional derivative thereof, is useful as a relatively non-hygroscopic selective inhibitor of inducible nitric oxice synthase. 1
    式(I)的化合物:即(2S)-2-基-4-[2-(乙基亚胺基)乙基]丁酸,与磷酸化合物,或其溶剂合物或生理功能衍生物一起使用,可作为相对不吸湿的选择性诱导型一氧化氮合酶抑制剂
  • [EN] NITRIC OXIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE MONOXYDE D'AZOTE SYNTHETASE
    申请人:GLAXO GROUP LIMITED
    公开号:WO1998030537A1
    公开(公告)日:1998-07-16
    (EN) The present invention relates to novel amidino compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.(FR) L'invention concerne de nouveaux composés d'amidino représentés par la formule (I), un procédé servant à les préparer, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique, en particulier, en tant qu'inhibiteurs sélectifs de la monoxyde d'azote synthétase inductible.
    本发明涉及一种新的化合物,为公式(I)所示的酰胺化合物,以及制备它们的方法,包含它们的药物组合物和它们作为选择性抑制诱导型一氧化氮合酶的治疗用途,特别是作为选择性抑制诱导型一氧化氮合酶的药物。
  • [EN] NITRIC OXIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE SYNTHASE D'OXYDE NITRIQUE
    申请人:GLAXO GROUP LIMITED
    公开号:WO1999062875A1
    公开(公告)日:1999-12-09
    (EN) The present invention relates to novel amidino compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof; wherein R1 is selected from C1-4 alkyl, C3-4 cycloalkyl, C1-4 hydroxyalkyl, and C1-4 haloalkyl; to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.(FR) L'invention concerne de nouveaux composés d'amidino représentés par la formule (I) ou un de leurs sels, solvates ou dérivés fonctionnels sur le plan physiologique ; dans laquelle R1 est sélectionné dans alkyle C1-C4, cycloalkyle C3-C4, hydroxyalkyle C1-C4 et haloalkyle C1-C4; un procédé servant à les préparer, des compositions pharmaceutiques les contenant et leur mise en application thérapeutique, en particulier, en tant qu'inhibiteurs sélectifs de synthase inductible d'oxyde nitrique.
    本发明涉及一种新型的amidino化合物,其化学式为(I),或其盐、溶剂化合物或生理功能衍生物;其中R1选自C1-4烷基、C3-4环烷基、C1-4羟基烷基和C1-4卤代烷基;以及制备它们的方法、含有它们的制药组合物,以及它们在治疗中的应用,特别是它们作为诱导型一氧化氮合酶的选择性抑制剂
  • Development of a Supply Route for the Synthesis of an iNOS Inhibitor: Complications of the Key S<sub>N</sub>2 Reaction
    作者:Geracimos Rassias、Stephen A. Hermitage、Mahesh J. Sanganee、Peter M. Kincey、Neil M. Smith、Ian P. Andrews、Gary T. Borrett、Graham R. Slater
    DOI:10.1021/op900108b
    日期:2009.7.17
    The original medicinal chemistry synthesis of an iNOS inhibitor presented several challenges that had to be overcome in order to constitute a supply route suitable for operation on a multikilo scale. The key step in the synthesis is an S(N)2 reaction that assembles the chiral carbon framework, but this reaction proved far more complex than we anticipated. significant improvements were made to all stages. The modified route performed well over two pilot-plant campaigns and delivered over 250 kg of the active pharmaceutical ingredient (API).
查看更多